Notably, no correlation was found between disease progression and plasma periostin levels [61], however, plasma periostin was found to significantly correlate with the improved lung function (measured by FEV1) of emphysema patients undergoing treatment of inhaled corticosteroids and long-acting beta antagonists [62]. This evidence concerns the gene POSTN and pulmonary emphysema.